Blood cancer is actually a term applied to three different types of cancer – leukemia, lymphoma and myeloma. For centuries, these cancers had...
Myeloma NZ
Reducing the Risk of Blood Clots in Patients With Multiple Myeloma
Patients with multiple myeloma are at risk of developing thrombosis (blood clots) that are associated with some newer treatments, according to two...
Myeloma Seminar for Patients, Families and Friends
Emerging Treatments for Patients with Myeloma Prove Promising Despite Obstacles
Myeloma is a complicated cancer type that can be tough to find a treatment option for which patients will respond to. However, in the past several...
Government unveils national cancer agency and $60 million injection into Pharmac
The Government has today unveiled plans to establish a national cancer agency, which will be led directly by experts of the deadly disease, and a...
Blood cancer more likely to affect relatives of people who have it, study shows
Close relatives of people with blood cancer are more likely to be diagnosed with the disease themselves, a major study has found. An international...
Multiple Myeloma Research Review
Highlights include: • Increased novel agent access in NZ improved MM survival • Pomalidomide-based regimens for relapsed/refractory MM •...
Suboptimal Implementation of Supportive Care in Older Patients With Multiple Myeloma
According to findings from a study published in Cancer on the utilization of specific supportive care measures in older patients with multiple...
Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry
Renal impairment (RI) is a poor prognostic factor in patients with multiple myeloma (MM). Despite improvements in survival with the introduction of...
Another myeloma drug with same target as CAR-Ts shows successful Phase II results
A Phase II study of a GlaxoSmithKline drug to treat the blood cancer multiple myeloma has been successful, the company said Friday. The London-based...
Dual CAR T-cell combination a ‘promising treatment option’ for multiple myeloma
A combination of humanized anti-CD19 and anti-B-cell maturation antigen chimeric antigen receptor T-cells has shown activity in patients with...
Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data
Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with...